Potential economic consequences of a cardioprotective agent for XXXX with @entity583 : modelling study.

@entity1 @entity583 @entity712 @entity1188
OBJECTIVE: To investigate the cost-effectiveness of a hypothetical cardioprotective agent used to reduce @entity1188 size in @entity1 undergoing percutaneous coronary intervention (PCI) after anterior ST-elevation @entity583 . METHODS: Design: A cost-utility analysis using a Markov model. SETTING: The National Health Service in the UK. @entity1 : @entity1 undergoing PCI after anterior ST-elevation @entity583 . INTERVENTIONS: A cardioprotective agent given at the time of reperfusion compared to no cardioprotection. We assumed the cardioprotective agent (given at the time of reperfusion) would reduce the risk and severity of @entity712 ( @entity712 ) after PCI and the risk of mortality after PCI (with a relative risk ranging from 0.6 to 1). The costs of the cardioprotective agent were assumed to be in the range   1000-4000. MAIN OUTCOME MEASURES: The incremental costs per quality-adjusted life-year (QALY) gained, using 95% CIs from 1000 simulations. RESULTS: Incremental costs ranged from   933 to   3820 and incremental QALYs from 0.04 to 0.38. The incremental cost-effectiveness ratio (ICER) ranged from   3311 to   63   480 per QALY gained. The results were highly dependent on the costs of a cardioprotective agent, @entity1 age, and the relative risk of @entity712 after PCI. The ICER was below the willingness-to-pay threshold of   20   000 per QALY gained in 71% of the simulations. CONCLUSIONS: A cardioprotective agent that can reduce the risk of @entity712 and mortality after PCI has a high chance of being cost-effective. This chance depends on the price of the agent, the age of the @entity1 and the relative risk of @entity712 after PCI.
